Jump to content

bioMérieux

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Nightstallion (talk | contribs) at 10:27, 12 May 2021 (fix title). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

bioMérieux SA
Company typeSociété Anonyme
Euronext: BIM
CAC Next 20 component
IndustryBiotechnology
Founded1963; 61 years ago (1963)
FounderDr Alain Mérieux
HeadquartersMarcy-l'Étoile, France
Area served
Worldwide
Key people
Alexandre Mérieux (CEO)
Dr Marcel Mérieux
Dr Charles Mérieux
Productsin vitro diagnostics
Revenue€3.1 billion (2020)
587,000,000 Euro (2022) Edit this on Wikidata
452,000,000 Euro (2022) Edit this on Wikidata
Number of employees
12,800 (2020)
Websitewww.biomerieux.com

bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.[1]

bioMérieux provides diagnostic solutions (reagents, instruments, softwares, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.[2] bioMérieux is listed on the NYSE Euronext Paris stock exchange (BIM – ISIN: FR0010096479).[2]

Revenue

bioMérieux had revenues of €3.1 billion as of 2020 with 93% of sales occurring outside France.[3]

History

In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux. In 1963 Alain Mérieux founded BD Mérieux, of which he assumed total control in 1973. BD Mérieux would later become bioMérieux. The company expanded its services and offerings through product development, acquisitions and partnerships:

  • Api Systems, acquired in 1986[citation needed]
  • Vitek Systems, acquired in 1988[citation needed]
  • Organon Teknika, acquired in 2001 from Akzo Nobel[4]
  • Bacterial Barcodes, acquired in 2006[5]
  • Biomedics (Spain) and BTF (Australia), acquired in 2007[6]
  • AB Biodisk (Sweden), AviaraDx (bioTheragnostics today) (USA) and PML Microbiologicals (USA), acquired in 2008[7]
  • Meikang Biotech and of Shanghai Zenka Biotechnology, acquired in 2010[8]
  • AES Laboratoire and Argene (France), acquired in 2011[9]
  • RAS (India), a specialist in molecular biology, acquired in 2012
  • Partnership with Quanterix in 2012 for the development of a new generation of ultrasensitive, multiplex immunoassays.[10]
  • BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology,[11][12] acquired in 2014
  • BioMerieux molecular biology affiliate BioFire, LLC. opened the Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, Utah[13] in 2017
  • Invisible Sentinel, A Philadelphia life sciences company that develops novel technology to quickly detect pathogens in food and beverages including wine and beer.[14]

Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Belingard is President, and Alexandre Mérieux is General Director.[2] bioMérieux was listed on the stock exchange in 2004.[15]

Shareholders

As of February 2021:[16]

Nom
Institut Mérieux 58.9%
Groupe Dassault 4.6%
GIMD 4.6%
Sofina 2.1%
Employees 0.6%

References

  1. ^ "Company Profile". Euronext.{{cite web}}: CS1 maint: url-status (link)
  2. ^ a b c "Stocks". Bloomberg.com. Retrieved 2020-11-03.
  3. ^ "2020 Financial Results" (PDF). bioMérieux Corporate Website.
  4. ^ "Akzo Nobel transfers Organon Teknika's diagnostics business to bioMérieux | AkzoNobel". www.akzonobel.com. Retrieved 2020-11-03.
  5. ^ "Archived copy". Archived from the original on 2017-11-07. Retrieved 2017-11-01.{{cite web}}: CS1 maint: archived copy as title (link)
  6. ^ "Biomerieux S.A. Acquires BTF Pty. | Mergr". mergr.com. Retrieved 2020-11-03.
  7. ^ Reuters Staff (2008-12-08). "BioMerieux buys U.S. microbiology firm". Reuters. Retrieved 2020-11-03. {{cite news}}: |author= has generic name (help)
  8. ^ "Pharma commercial intelligence, news & analysis | Evaluate". www.evaluate.com. Retrieved 2020-11-03.
  9. ^ "BioMérieux Acquires AES Laboratoire". Quality Assurance & Food Safety. Retrieved 2020-11-03.
  10. ^ "bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays | Quanterix". www.quanterix.com. Retrieved 2020-11-03.
  11. ^ "BioMerieux Finalizes BioFire Diagnostics Acquisition". GenomeWeb. Retrieved 2020-11-03.
  12. ^ Reuters Staff (2013-09-04). "BioMerieux buys diagnostics rival BioFire for $450 mln". Reuters. Retrieved 2020-11-03. {{cite news}}: |author= has generic name (help)
  13. ^ Jun 29, Elaine Sanchez Wilson |; Diagnostics | 0 |, 2017 | Molecular (2017-06-30). "BioFire Opens Center for Molecular Diagnostics". Clinical Lab Product. Retrieved 2020-11-03.{{cite web}}: CS1 maint: numeric names: authors list (link)
  14. ^ "$75 million deal: Invisible Sentinel sold to French biotech company". www.bizjournals.com. Retrieved 2020-11-03.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "Archived copy". Archived from the original on 2017-11-07. Retrieved 2017-11-01.{{cite web}}: CS1 maint: archived copy as title (link)
  16. ^ Bourse, Zone. "Boursorama". www.boursorama.com (in French). Retrieved 2021-02-24.
Retrieved from "https://en.wikipedia.org/w/index.php?title=BioMérieux&oldid=1022763653"